151 related articles for article (PubMed ID: 11294564)
1. IL-10 promoter polymorphisms influence tumour development in cutaneous malignant melanoma.
Howell WM; Turner SJ; Bateman AC; Theaker JM
Genes Immun; 2001 Feb; 2(1):25-31. PubMed ID: 11294564
[TBL] [Abstract][Full Text] [Related]
2. Influence of vascular endothelial growth factor single nucleotide polymorphisms on tumour development in cutaneous malignant melanoma.
Howell WM; Bateman AC; Turner SJ; Collins A; Theaker JM
Genes Immun; 2002 Jun; 3(4):229-32. PubMed ID: 12058259
[TBL] [Abstract][Full Text] [Related]
3. ICAM-1 polymorphisms and development of cutaneous malignant melanoma.
Howell WM; Rose-Zerilli MJ; Theaker JM; Bateman AC
Int J Immunogenet; 2005 Dec; 32(6):367-73. PubMed ID: 16313300
[TBL] [Abstract][Full Text] [Related]
4. Cytokine gene polymorphisms and breast cancer susceptibility and prognosis.
Smith KC; Bateman AC; Fussell HM; Howell WM
Eur J Immunogenet; 2004 Aug; 31(4):167-73. PubMed ID: 15265021
[TBL] [Abstract][Full Text] [Related]
5. Polymorphisms of the FAS and FAS ligand genes associated with risk of cutaneous malignant melanoma.
Li C; Larson D; Zhang Z; Liu Z; Strom SS; Gershenwald JE; Prieto VG; Lee JE; Ross MI; Mansfield PF; Cormier JN; Duvic M; Grimm EA; Wei Q
Pharmacogenet Genomics; 2006 Apr; 16(4):253-63. PubMed ID: 16538172
[TBL] [Abstract][Full Text] [Related]
6. Influence of interleukin-8 and interleukin-10 on sporadic colon cancer development and progression.
Cacev T; Radosević S; Krizanac S; Kapitanović S
Carcinogenesis; 2008 Aug; 29(8):1572-80. PubMed ID: 18628251
[TBL] [Abstract][Full Text] [Related]
7. Cytokine gene single nucleotide polymorphisms and susceptibility to and prognosis in cutaneous malignant melanoma.
Howell WM; Turner SJ; Theaker JM; Bateman AC
Eur J Immunogenet; 2003 Dec; 30(6):409-14. PubMed ID: 14675394
[TBL] [Abstract][Full Text] [Related]
8. Influence of TNFalpha and LTalpha single nucleotide polymorphisms on susceptibility to and prognosis in cutaneous malignant melanoma in the British population.
Howell WM; Turner SJ; Collins A; Bateman AC; Theaker JM
Eur J Immunogenet; 2002 Feb; 29(1):17-23. PubMed ID: 11841484
[TBL] [Abstract][Full Text] [Related]
9. An interleukin-10 promoter polymorphism may influence tumor development in renal cell carcinoma.
Havranek E; Howell WM; Fussell HM; Whelan JA; Whelan MA; Pandha HS
J Urol; 2005 Mar; 173(3):709-12. PubMed ID: 15711248
[TBL] [Abstract][Full Text] [Related]
10. Gene expression profiling of primary cutaneous melanoma.
Winnepenninckx V; Van den Oord JJ
Verh K Acad Geneeskd Belg; 2007; 69(1):23-45. PubMed ID: 17427873
[TBL] [Abstract][Full Text] [Related]
11. A polymorphism in the interleukin-10 promoter affects the course of disease in patients with clear-cell renal carcinoma.
Romero JM; Sáenz-López P; Cózar JM; Carretero R; Canton J; Vazquez F; Concha A; Tallada M; Garrido F; Ruiz-Cabello F
Hum Immunol; 2009 Jan; 70(1):60-4. PubMed ID: 19027043
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-10 gene promoter polymorphisms and the risk of nasopharyngeal carcinoma.
Wei YS; Kuang XH; Zhu YH; Liang WB; Yang ZH; Tai SH; Zhao Y; Zhang L
Tissue Antigens; 2007 Jul; 70(1):12-7. PubMed ID: 17559576
[TBL] [Abstract][Full Text] [Related]
13. The broad effects of the functional IL-10 promoter-592 polymorphism: modulation of IL-10, TIMP-3, and OPG expression and their association with periodontal disease outcome.
Claudino M; Trombone AP; Cardoso CR; Ferreira SB; Martins W; Assis GF; Santos CF; Trevilatto PC; Campanelli AP; Silva JS; Garlet GP
J Leukoc Biol; 2008 Dec; 84(6):1565-73. PubMed ID: 18725394
[TBL] [Abstract][Full Text] [Related]
14. Polymorphisms of the neuronal and inducible nitric oxide synthase genes and the risk of cutaneous melanoma: a case-control study.
Li C; Hu Z; Liu Z; Wang LE; Gershenwald JE; Lee JE; Prieto VG; Duvic M; Grimm EA; Wei Q
Cancer; 2007 Apr; 109(8):1570-8. PubMed ID: 17328085
[TBL] [Abstract][Full Text] [Related]
15. Renovascular disease is associated with low producer genotypes of the anti-inflammatory cytokine interleukin-10.
George S; Ruan XZ; Navarrete C; Turner D; Reynard M; Sweny P; Hamilton G; Wheeler DC; Powis SH; Moorhead JF; Varghese Z
Tissue Antigens; 2004 May; 63(5):470-5. PubMed ID: 15104679
[TBL] [Abstract][Full Text] [Related]
16. Single nucleotide polymorphisms in DNA repair genes XRCC1 and APEX1 in progression and survival of primary cutaneous melanoma patients.
Figl A; Scherer D; Nagore E; Bermejo JL; Dickes E; Thirumaran RK; Gast A; Hemminki K; Kumar R; Schadendorf D
Mutat Res; 2009 Feb; 661(1-2):78-84. PubMed ID: 19073198
[TBL] [Abstract][Full Text] [Related]
17. Polymorphisms in tumour necrosis factor-alpha, transforming growth factor-beta, interleukin-10, interleukin-6, interferon-gamma, and outcome of hepatitis C virus infection.
Barrett S; Collins M; Kenny C; Ryan E; Keane CO; Crowe J
J Med Virol; 2003 Oct; 71(2):212-8. PubMed ID: 12938195
[TBL] [Abstract][Full Text] [Related]
18. Differential effect of IL10 and TNF{alpha} genotypes on determining susceptibility to discoid and systemic lupus erythematosus.
Suárez A; López P; Mozo L; Gutiérrez C
Ann Rheum Dis; 2005 Nov; 64(11):1605-10. PubMed ID: 15800006
[TBL] [Abstract][Full Text] [Related]
19. The polymorphisms of interleukin-10 gene influence the prognosis of patients with advanced melanoma.
Vuoristo MS
Cancer Genet Cytogenet; 2007 Jul; 176(1):54-7. PubMed ID: 17574964
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-10 promoter polymorphisms are associated with the mode and sequel of HBeAg seroconversion in patients with chronic hepatitis B virus infection.
Peng XM; Huang YS; Ma HH; Gu L; Xie QF; Gao ZL
Liver Int; 2006 Apr; 26(3):326-33. PubMed ID: 16584395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
